Literature DB >> 17727367

Characteristics of acquired reactive perforating collagenosis.

Hiromi Tsuboi1, Kensei Katsuoka.   

Abstract

The status of the patient's associated disease can generally affect the onset or healing of acquired reactive perforating collagenosis (ARPC). We treated eight cases of ARPC and noted that the patients had similar findings. However, it was not clear why ARPC developed in the patients with these diseases. Nevertheless, several factors related to the diseases associated with ARPC could affect the degeneration of collagen fibers or the production of dermal products. Some patients had diseases that were characterized by fibrosis and an increased amount of reticular fibers. Factors related to tissue remodeling might act not only in diseases associated with ARPC but also in ARPC itself.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17727367     DOI: 10.1111/j.1346-8138.2007.00346.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  5 in total

Review 1.  Cutaneous manifestations of ESRD.

Authors:  Timur A Galperin; Antonia J Cronin; Kieron S Leslie
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

2.  Giant acquired reactive perforating collagenosis in a patient with diabetes mellitus and metastatic breast carcinoma.

Authors:  Randie H Kim; Maryann Kwa; Sylvia Adams; Shane A Meehan; Jennifer A Stein
Journal:  JAAD Case Rep       Date:  2016-01-14

3.  Acquired reactive perforating collagenosis: A report of a typical case.

Authors:  Chengwen Fei; Yao Wang; Yu Gong; Hui Xu; Qian Yu; Yuling Shi
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

4.  Acquired reactive perforating collagenosis in association with prostate adenocarcinoma, chronic lymphocytic leukemia, and Graves' disease.

Authors:  Leyla Huseynova; Neslihan Akdogan; Özay Gököz; Sibel Ersoy Evans
Journal:  An Bras Dermatol       Date:  2020-04-18       Impact factor: 1.896

5.  Tacalcitol in the treatment of acquired perforating collagenosis.

Authors:  J C Escribano-Stablé; C Doménech; J Matarredona; J C Pascual; A Jaen; J Vicente
Journal:  Case Rep Dermatol       Date:  2014-02-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.